eligibility_summary
Adults (≥18) with r/r large B‑cell lymphoma, relapsing ≤12 mo after 1L or after ≥2 lines, measurable disease. Therapy washouts incl checkpoint, steroids 7 d. ECOG 0–2, adequate marrow/renal/hepatic/cardiac/pulmonary function. Exclude: active cancer/Richter, auto‑/allo‑SCT, active infections incl HBV/HCV/TB/CMV/EBV/AdV, CNS disease, major cardiac events or PE, severe allergy, pregnant/lactating, autoimmune needing immunosuppression/biologics, recent BCG/live vaccines, investigational therapy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2 single-arm study testing prophylactic emapalumab to prevent CAR‑T–associated toxicities in adults receiving axicabtagene ciloleucel for relapsed/refractory large B‑cell lymphomas. Interventions and mechanisms: 1) Emapalumab (Gamifant), a fully human anti–IFN‑γ monoclonal antibody (cytokine inhibitor) that neutralizes IFN‑γ, attenuating JAK/STAT1‑mediated macrophage/Th1 activation and the inflammatory cascade driving CRS/ICANS. 2) Axicabtagene ciloleucel, an autologous CD19‑directed CAR‑T cell therapy (CD28 costimulation) that kills CD19+ malignant B cells. 3) Lymphodepletion with fludarabine (purine antimetabolite) and cyclophosphamide (alkylating agent) to reduce host lymphocytes and support CAR‑T expansion. Targets/pathways: CD19+ B cells, IFN‑γ signaling, monocyte/macrophage activation, T‑cell cytokine release.